Here we used a rodent model of type 2 diabetes (UCD‐T2DM rats) to investigate whether GH supplementation could augment the anti‐diabetic effects of liraglutide (a GLP‐1 receptor agonist) treatment. The gene discussed is GH1; the disease is urea cycle disorder.